First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
The partnership will provide health plans with an out-of-the-box compliance solution for CMS-9115 and CMS-0057 rules
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
These accolades highlight our unwavering commitment to maintaining the highest safety standards
Subscribe To Our Newsletter & Stay Updated
